We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Poor Trial Enrollment Hurts Cell Therapeutics’ Pixuvri
An FDA advisory committee has voted unanimously that Cell Therapeutics’ single, incomplete trial is inadequate to support approval of its non-Hodgkin’s
lymphoma (NHL) drug Pixuvri.